ReviewWorld journal of hepatology2018
Contemporary role of liver biopsy in hepatocellular carcinoma.
Review in World journal of hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center.PloS one · 2019Trial
- CT-based habitat imaging integrated with radiomics and clinicopathology for noninvasive prediction of microvascular invasion in hepatocellular carcinoma.Frontiers in oncology · 2026Article
- Advancing precision medicine in hepatocellular carcinoma: current challenges and future directions in liquid biopsy, immune microenvironment, single nucleotide polymorphisms, and conversion therapy.Hepatic oncology · 2025Review
- Noninvasive prediction of Glypican-3 expression in hepatocellular carcinoma using Habitat-based and peritumoral CT radiomics: a nomogram approach.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- From texture analysis to artificial intelligence: global research landscape and evolutionary trajectory of radiomics in hepatocellular carcinoma.Discover oncology · 2025Article
- Pragmatic Approach to Hepatocellular Carcinoma Diagnosis in High-Incidence, Resource-Limited Settings in Africa.JCO global oncology · 2025Article
- Hepatocellular Carcinoma With Tumor Thrombus Extension Into the Right Atrium of the Heart.Cureus · 2023Article
- Refining Liver Biopsy in Hepatocellular Carcinoma: An In-Depth Exploration of Shifting Diagnostic and Therapeutic Applications.Biomedicines · 2023Review
- Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review.Clinical and molecular hepatology · 2022Review
- A Scoring System for Predicting Microvascular Invasion in Hepatocellular Carcinoma Based on Quantitative Functional MRI.Journal of clinical medicine · 2022Article
- Segmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers.Diagnostics (Basel, Switzerland) · 2022Article
- Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion.Journal of cancer research and clinical oncology · 2022Article
- Electromagnetic Tracking and Optical Molecular Imaging Guidance for Liver Biopsy and Point-of-Care Tissue Assessment in Phantom and Woodchuck Hepatocellular Carcinoma.Cardiovascular and interventional radiology · 2021Article
- Is There a Place for Elastography in the Diagnosis of Hepatocellular Carcinoma?Journal of clinical medicine · 2021Article
- Challenges in Diagnosis of Hepatocellular Carcinoma in Cirrhotic Liver: A Pathologist's Perspective.Clinical liver disease · 2021Review
- The Need for Alternatives to Liver Biopsies: Non-Invasive Analytics and Diagnostics.Hepatic medicine : evidence and research · 2021Review
- Identification of hub genes in peripheral blood mononuclear cells for the diagnosis of hepatocellular carcinoma using a weighted gene co-expression network analysis.Experimental and therapeutic medicine · 2020Article
- Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?Journal of clinical medicine · 2020Review
- Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience.Annals of gastroenterological surgery · 2020Review
- Differences in Pathology, Staging, and Treatment between HIVCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A correct diagnosis of hepatocellular carcinoma (HCC) in cirrhotic patients with focal liver lesions is one of the most important issues nowadays. Probably one of the oldest debates in the hepatology community is whether to perform liver biopsy (LB) in all cirrhotic patients with focal liver lesions. We now face a time when oncology is moving towards personalized medicine. According to the current European Association for the study of Liver diseases HCC guidelines, LB has only a minor role in the management of HCC. However, the current recommendations were made more than five years ago. As time has passed, the development of high-throughput molecular technologies has helped reveal the main molecular mechanism involved in HCC development and progression. Several subtypes of HCC, with both molecular and histological characterization, have been described. Importantly, some of these subtypes have prognostic impact. In the context of personalized treatment, the role of LB will be carefully reconsidered. Until then, it is mandatory to know the various techniques of LB, their performances, complications and limitations. The balance of risk and benefit defines many of the decisions that we make as providers of medical care. In this review, we discuss not only the risks associated with LB, but also the benefits of biopsy in various clinical scenarios. Not long from now, the role of LB will be reconsidered. It is possible that we will go back in time and once again use biopsy for HCC diagnosis. Then again, we may move back to the future to try to improve the use of liquid biopsy in the follow-up of HCC patients after various treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.